Levofloxacin might be safe to use for OSCC patients
Oral squamous cell carcinoma patients are exhausted against the powerful chemotherapies, radiotherapies after the surgery, and their immune system is devastated during the process and antibiotic usage become inescapable. Although prescribing an antibiotic might be fraught for such as drug interactio...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2021-08, Vol.38 (8), p.87-87, Article 87 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 87 |
|---|---|
| container_issue | 8 |
| container_start_page | 87 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 38 |
| creator | Aydemir, Levent Iplik, Elif Sinem Ertugrul, Baris Kasarci, Goksu Atas, Merve Nur Ulusan, Murat Ergen, Arzu Cakmakoglu, Bedia |
| description | Oral squamous cell carcinoma patients are exhausted against the powerful chemotherapies, radiotherapies after the surgery, and their immune system is devastated during the process and antibiotic usage become inescapable. Although prescribing an antibiotic might be fraught for such as drug interaction and undesirable proliferation danger, studies still look for the new ideas such as antibiotic combinations that might be safe to use. The antiproliferative and apoptotic outcomes of levofloxacin with cisplatin combination as well as their single usage were examined with WST-1, Caspase-3/BCA and Annexin V methods on SCC-15 cells and a healthy cell line (MRC-5). 24 h treatment of 50 mM single levofloxacin, 50 mM single cisplatin and 50 mM levofloxacin-cisplatin combination resulted in viability rates of SCC-15 cells as 90%, 67% and 80.8%, respectively. Caspase-3 enzyme activity was enhanced 0.92-fold for single levofloxacin, 13.05-fold for single cisplatin and 9.73-fold for the combination of levofloxacin-cisplatin, the total apoptotic activity of single levofloxacin, single cisplatin and levofloxacin-cisplatin combination were observed as 4.88%, 21.14%, 16.21%, respectively on SCC-15. The apoptotic effect of cisplatin on MRC-5 has been shown to be suppressed when combined with levofloxacin. Considering the cell viability, caspase-3, and apoptotic activity results, it’s conclude that the levofloxacin-cisplatin combination was also effective compared to the only cisplatin treatment on OSCC cells. The combination has shown less toxicity for healthy cells than single cisplatin treatment. Therefore, our apoptotic findings suggest that the different dosage combinations are necessary to understand the interaction for the treatment of tongue squamous cell carcinoma. |
| doi_str_mv | 10.1007/s12032-021-01538-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2545602754</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2545004242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-a40dca10387f714d02a7ad16aa783a9504b6d67ce6c0302c4180b7674519b9763</originalsourceid><addsrcrecordid>eNp9kE1LxDAURYMozjj6B1xIwI2b6MtX0y6l-AUDs1DBXUjbdOzQNmPTiv57M9NRwYWrBHLuzXsHoVMKlxRAXXnKgDMCjBKgkseE7aEplTIhlNOX_XDnUhGQEUzQkfcrCKRkySGacEEVCEmniM_tuytr92HyqsVNtXztcWaxN6XFvcODt7h0HV48pilem76ybe-P0UFpam9PducMPd_ePKX3ZL64e0iv5yQXNOmJEVDkhgKPVamoKIAZZQoaGaNibhIJIouKSOU2yoEDC6EYMhWpMFeSJSriM3Qx9q479zZY3-um8rmta9NaN3jNpAi7MSVFQM__oCs3dG2YbksBCCZYoNhI5Z3zvrOlXndVY7pPTUFvlOpRqQ6i9Fap3oTOdtVD1tjiJ_LtMAB8BHx4ape2-_37n9ov_U19gA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2545004242</pqid></control><display><type>article</type><title>Levofloxacin might be safe to use for OSCC patients</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Aydemir, Levent ; Iplik, Elif Sinem ; Ertugrul, Baris ; Kasarci, Goksu ; Atas, Merve Nur ; Ulusan, Murat ; Ergen, Arzu ; Cakmakoglu, Bedia</creator><creatorcontrib>Aydemir, Levent ; Iplik, Elif Sinem ; Ertugrul, Baris ; Kasarci, Goksu ; Atas, Merve Nur ; Ulusan, Murat ; Ergen, Arzu ; Cakmakoglu, Bedia</creatorcontrib><description>Oral squamous cell carcinoma patients are exhausted against the powerful chemotherapies, radiotherapies after the surgery, and their immune system is devastated during the process and antibiotic usage become inescapable. Although prescribing an antibiotic might be fraught for such as drug interaction and undesirable proliferation danger, studies still look for the new ideas such as antibiotic combinations that might be safe to use. The antiproliferative and apoptotic outcomes of levofloxacin with cisplatin combination as well as their single usage were examined with WST-1, Caspase-3/BCA and Annexin V methods on SCC-15 cells and a healthy cell line (MRC-5). 24 h treatment of 50 mM single levofloxacin, 50 mM single cisplatin and 50 mM levofloxacin-cisplatin combination resulted in viability rates of SCC-15 cells as 90%, 67% and 80.8%, respectively. Caspase-3 enzyme activity was enhanced 0.92-fold for single levofloxacin, 13.05-fold for single cisplatin and 9.73-fold for the combination of levofloxacin-cisplatin, the total apoptotic activity of single levofloxacin, single cisplatin and levofloxacin-cisplatin combination were observed as 4.88%, 21.14%, 16.21%, respectively on SCC-15. The apoptotic effect of cisplatin on MRC-5 has been shown to be suppressed when combined with levofloxacin. Considering the cell viability, caspase-3, and apoptotic activity results, it’s conclude that the levofloxacin-cisplatin combination was also effective compared to the only cisplatin treatment on OSCC cells. The combination has shown less toxicity for healthy cells than single cisplatin treatment. Therefore, our apoptotic findings suggest that the different dosage combinations are necessary to understand the interaction for the treatment of tongue squamous cell carcinoma.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-021-01538-2</identifier><identifier>PMID: 34170451</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibiotics ; Antineoplastic Agents - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Bacterial infections ; Cancer therapies ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - pathology ; Cell Line, Tumor ; Cell Survival - drug effects ; Cell Survival - physiology ; Chemotherapy ; Cisplatin - administration & dosage ; Drug dosages ; Drug resistance ; Hematology ; Human papillomavirus ; Humans ; Infections ; Internal Medicine ; Levofloxacin - administration & dosage ; Localization ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastasis ; Mouth Neoplasms - drug therapy ; Mouth Neoplasms - pathology ; Oncology ; Oral cancer ; Original Paper ; Otolaryngology ; Pathology ; Squamous cell carcinoma ; Tongue ; Tongue Neoplasms - drug therapy ; Tongue Neoplasms - pathology</subject><ispartof>Medical oncology (Northwood, London, England), 2021-08, Vol.38 (8), p.87-87, Article 87</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-a40dca10387f714d02a7ad16aa783a9504b6d67ce6c0302c4180b7674519b9763</citedby><cites>FETCH-LOGICAL-c419t-a40dca10387f714d02a7ad16aa783a9504b6d67ce6c0302c4180b7674519b9763</cites><orcidid>0000-0001-5736-8453 ; 0000-0001-7960-9131 ; 0000-0002-5836-4304 ; 0000-0001-9766-4361 ; 0000-0003-3878-1829 ; 0000-0001-5045-5095 ; 0000-0003-3465-1808 ; 0000-0003-3885-1620</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-021-01538-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-021-01538-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27911,27912,41475,42544,51306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34170451$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aydemir, Levent</creatorcontrib><creatorcontrib>Iplik, Elif Sinem</creatorcontrib><creatorcontrib>Ertugrul, Baris</creatorcontrib><creatorcontrib>Kasarci, Goksu</creatorcontrib><creatorcontrib>Atas, Merve Nur</creatorcontrib><creatorcontrib>Ulusan, Murat</creatorcontrib><creatorcontrib>Ergen, Arzu</creatorcontrib><creatorcontrib>Cakmakoglu, Bedia</creatorcontrib><title>Levofloxacin might be safe to use for OSCC patients</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Oral squamous cell carcinoma patients are exhausted against the powerful chemotherapies, radiotherapies after the surgery, and their immune system is devastated during the process and antibiotic usage become inescapable. Although prescribing an antibiotic might be fraught for such as drug interaction and undesirable proliferation danger, studies still look for the new ideas such as antibiotic combinations that might be safe to use. The antiproliferative and apoptotic outcomes of levofloxacin with cisplatin combination as well as their single usage were examined with WST-1, Caspase-3/BCA and Annexin V methods on SCC-15 cells and a healthy cell line (MRC-5). 24 h treatment of 50 mM single levofloxacin, 50 mM single cisplatin and 50 mM levofloxacin-cisplatin combination resulted in viability rates of SCC-15 cells as 90%, 67% and 80.8%, respectively. Caspase-3 enzyme activity was enhanced 0.92-fold for single levofloxacin, 13.05-fold for single cisplatin and 9.73-fold for the combination of levofloxacin-cisplatin, the total apoptotic activity of single levofloxacin, single cisplatin and levofloxacin-cisplatin combination were observed as 4.88%, 21.14%, 16.21%, respectively on SCC-15. The apoptotic effect of cisplatin on MRC-5 has been shown to be suppressed when combined with levofloxacin. Considering the cell viability, caspase-3, and apoptotic activity results, it’s conclude that the levofloxacin-cisplatin combination was also effective compared to the only cisplatin treatment on OSCC cells. The combination has shown less toxicity for healthy cells than single cisplatin treatment. Therefore, our apoptotic findings suggest that the different dosage combinations are necessary to understand the interaction for the treatment of tongue squamous cell carcinoma.</description><subject>Antibiotics</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Bacterial infections</subject><subject>Cancer therapies</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Cell Survival - physiology</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Drug dosages</subject><subject>Drug resistance</subject><subject>Hematology</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Infections</subject><subject>Internal Medicine</subject><subject>Levofloxacin - administration & dosage</subject><subject>Localization</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Mouth Neoplasms - drug therapy</subject><subject>Mouth Neoplasms - pathology</subject><subject>Oncology</subject><subject>Oral cancer</subject><subject>Original Paper</subject><subject>Otolaryngology</subject><subject>Pathology</subject><subject>Squamous cell carcinoma</subject><subject>Tongue</subject><subject>Tongue Neoplasms - drug therapy</subject><subject>Tongue Neoplasms - pathology</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LxDAURYMozjj6B1xIwI2b6MtX0y6l-AUDs1DBXUjbdOzQNmPTiv57M9NRwYWrBHLuzXsHoVMKlxRAXXnKgDMCjBKgkseE7aEplTIhlNOX_XDnUhGQEUzQkfcrCKRkySGacEEVCEmniM_tuytr92HyqsVNtXztcWaxN6XFvcODt7h0HV48pilem76ybe-P0UFpam9PducMPd_ePKX3ZL64e0iv5yQXNOmJEVDkhgKPVamoKIAZZQoaGaNibhIJIouKSOU2yoEDC6EYMhWpMFeSJSriM3Qx9q479zZY3-um8rmta9NaN3jNpAi7MSVFQM__oCs3dG2YbksBCCZYoNhI5Z3zvrOlXndVY7pPTUFvlOpRqQ6i9Fap3oTOdtVD1tjiJ_LtMAB8BHx4ape2-_37n9ov_U19gA</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Aydemir, Levent</creator><creator>Iplik, Elif Sinem</creator><creator>Ertugrul, Baris</creator><creator>Kasarci, Goksu</creator><creator>Atas, Merve Nur</creator><creator>Ulusan, Murat</creator><creator>Ergen, Arzu</creator><creator>Cakmakoglu, Bedia</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5736-8453</orcidid><orcidid>https://orcid.org/0000-0001-7960-9131</orcidid><orcidid>https://orcid.org/0000-0002-5836-4304</orcidid><orcidid>https://orcid.org/0000-0001-9766-4361</orcidid><orcidid>https://orcid.org/0000-0003-3878-1829</orcidid><orcidid>https://orcid.org/0000-0001-5045-5095</orcidid><orcidid>https://orcid.org/0000-0003-3465-1808</orcidid><orcidid>https://orcid.org/0000-0003-3885-1620</orcidid></search><sort><creationdate>20210801</creationdate><title>Levofloxacin might be safe to use for OSCC patients</title><author>Aydemir, Levent ; Iplik, Elif Sinem ; Ertugrul, Baris ; Kasarci, Goksu ; Atas, Merve Nur ; Ulusan, Murat ; Ergen, Arzu ; Cakmakoglu, Bedia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-a40dca10387f714d02a7ad16aa783a9504b6d67ce6c0302c4180b7674519b9763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibiotics</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Bacterial infections</topic><topic>Cancer therapies</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Cell Survival - physiology</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Drug dosages</topic><topic>Drug resistance</topic><topic>Hematology</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Infections</topic><topic>Internal Medicine</topic><topic>Levofloxacin - administration & dosage</topic><topic>Localization</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Mouth Neoplasms - drug therapy</topic><topic>Mouth Neoplasms - pathology</topic><topic>Oncology</topic><topic>Oral cancer</topic><topic>Original Paper</topic><topic>Otolaryngology</topic><topic>Pathology</topic><topic>Squamous cell carcinoma</topic><topic>Tongue</topic><topic>Tongue Neoplasms - drug therapy</topic><topic>Tongue Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aydemir, Levent</creatorcontrib><creatorcontrib>Iplik, Elif Sinem</creatorcontrib><creatorcontrib>Ertugrul, Baris</creatorcontrib><creatorcontrib>Kasarci, Goksu</creatorcontrib><creatorcontrib>Atas, Merve Nur</creatorcontrib><creatorcontrib>Ulusan, Murat</creatorcontrib><creatorcontrib>Ergen, Arzu</creatorcontrib><creatorcontrib>Cakmakoglu, Bedia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aydemir, Levent</au><au>Iplik, Elif Sinem</au><au>Ertugrul, Baris</au><au>Kasarci, Goksu</au><au>Atas, Merve Nur</au><au>Ulusan, Murat</au><au>Ergen, Arzu</au><au>Cakmakoglu, Bedia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Levofloxacin might be safe to use for OSCC patients</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>38</volume><issue>8</issue><spage>87</spage><epage>87</epage><pages>87-87</pages><artnum>87</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><abstract>Oral squamous cell carcinoma patients are exhausted against the powerful chemotherapies, radiotherapies after the surgery, and their immune system is devastated during the process and antibiotic usage become inescapable. Although prescribing an antibiotic might be fraught for such as drug interaction and undesirable proliferation danger, studies still look for the new ideas such as antibiotic combinations that might be safe to use. The antiproliferative and apoptotic outcomes of levofloxacin with cisplatin combination as well as their single usage were examined with WST-1, Caspase-3/BCA and Annexin V methods on SCC-15 cells and a healthy cell line (MRC-5). 24 h treatment of 50 mM single levofloxacin, 50 mM single cisplatin and 50 mM levofloxacin-cisplatin combination resulted in viability rates of SCC-15 cells as 90%, 67% and 80.8%, respectively. Caspase-3 enzyme activity was enhanced 0.92-fold for single levofloxacin, 13.05-fold for single cisplatin and 9.73-fold for the combination of levofloxacin-cisplatin, the total apoptotic activity of single levofloxacin, single cisplatin and levofloxacin-cisplatin combination were observed as 4.88%, 21.14%, 16.21%, respectively on SCC-15. The apoptotic effect of cisplatin on MRC-5 has been shown to be suppressed when combined with levofloxacin. Considering the cell viability, caspase-3, and apoptotic activity results, it’s conclude that the levofloxacin-cisplatin combination was also effective compared to the only cisplatin treatment on OSCC cells. The combination has shown less toxicity for healthy cells than single cisplatin treatment. Therefore, our apoptotic findings suggest that the different dosage combinations are necessary to understand the interaction for the treatment of tongue squamous cell carcinoma.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34170451</pmid><doi>10.1007/s12032-021-01538-2</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5736-8453</orcidid><orcidid>https://orcid.org/0000-0001-7960-9131</orcidid><orcidid>https://orcid.org/0000-0002-5836-4304</orcidid><orcidid>https://orcid.org/0000-0001-9766-4361</orcidid><orcidid>https://orcid.org/0000-0003-3878-1829</orcidid><orcidid>https://orcid.org/0000-0001-5045-5095</orcidid><orcidid>https://orcid.org/0000-0003-3465-1808</orcidid><orcidid>https://orcid.org/0000-0003-3885-1620</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2021-08, Vol.38 (8), p.87-87, Article 87 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2545602754 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antibiotics Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Bacterial infections Cancer therapies Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Cell Line, Tumor Cell Survival - drug effects Cell Survival - physiology Chemotherapy Cisplatin - administration & dosage Drug dosages Drug resistance Hematology Human papillomavirus Humans Infections Internal Medicine Levofloxacin - administration & dosage Localization Medical prognosis Medicine Medicine & Public Health Metastasis Mouth Neoplasms - drug therapy Mouth Neoplasms - pathology Oncology Oral cancer Original Paper Otolaryngology Pathology Squamous cell carcinoma Tongue Tongue Neoplasms - drug therapy Tongue Neoplasms - pathology |
| title | Levofloxacin might be safe to use for OSCC patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T01%3A21%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Levofloxacin%20might%20be%20safe%20to%20use%20for%20OSCC%20patients&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Aydemir,%20Levent&rft.date=2021-08-01&rft.volume=38&rft.issue=8&rft.spage=87&rft.epage=87&rft.pages=87-87&rft.artnum=87&rft.issn=1357-0560&rft.eissn=1559-131X&rft_id=info:doi/10.1007/s12032-021-01538-2&rft_dat=%3Cproquest_cross%3E2545004242%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2545004242&rft_id=info:pmid/34170451&rfr_iscdi=true |